BACKGROUND: Complement is a central part of both the innate and adaptive immune response and its activation has traditionally been considered part of the immunosurveillance response against cancer. Its pro-inflammatory role and its contribution to the development of many illnesses associated with inflammatory states implicate complement in carcinogenesis. METHODS: We evaluated the role of three protein inhibitors of complement-cobra venom factor, humanized cobra venom factor, and recombinant staphylococcus aureus superantigen-like protein 7-in the setting of a transplantable murine colon cancer model. Outcomes were evaluated by monitoring tumor growth, and flow cytometry, ELISPOT, and quantitative real-time PCR were used to determine the impact of complement inhibition on the host immune response. RESULTS: Complement inhibitors were effective at depleting complement component C3 in tumor bearing mice and this was temporally correlated with a decreased rate of tumor growth during the establishment of tumors. Treatment with cobra venom factor resulted in increased CD8(+) T cells as a percentage of tumor-infiltrating cells as well as a reduced immunosuppressive environment evidenced by decreased myeloid derived suppressor cells in splenocytes of treated mice. Complement inhibition resulted in increased expression of the chemoattractive cytokines CCL5, CXCL10, and CXCL11. DISCUSSION: Complement depletion represents a promising mode of immunotherapy in cancer by its ability to impair tumor growth by increasing the host's effective immune response to tumor and diminishing the immunosuppressive effect created by the tumor microenvironment and ultimately could be utilized as a component of combination immunotherapy.
BACKGROUND: Complement is a central part of both the innate and adaptive immune response and its activation has traditionally been considered part of the immunosurveillance response against cancer. Its pro-inflammatory role and its contribution to the development of many illnesses associated with inflammatory states implicate complement in carcinogenesis. METHODS: We evaluated the role of three protein inhibitors of complement-cobra venom factor, humanized cobra venom factor, and recombinant staphylococcus aureus superantigen-like protein 7-in the setting of a transplantable murinecolon cancer model. Outcomes were evaluated by monitoring tumor growth, and flow cytometry, ELISPOT, and quantitative real-time PCR were used to determine the impact of complement inhibition on the host immune response. RESULTS: Complement inhibitors were effective at depleting complement component C3 in tumor bearing mice and this was temporally correlated with a decreased rate of tumor growth during the establishment of tumors. Treatment with cobra venom factor resulted in increased CD8(+) T cells as a percentage of tumor-infiltrating cells as well as a reduced immunosuppressive environment evidenced by decreased myeloid derived suppressor cells in splenocytes of treated mice. Complement inhibition resulted in increased expression of the chemoattractive cytokines CCL5, CXCL10, and CXCL11. DISCUSSION: Complement depletion represents a promising mode of immunotherapy in cancer by its ability to impair tumor growth by increasing the host's effective immune response to tumor and diminishing the immunosuppressive effect created by the tumor microenvironment and ultimately could be utilized as a component of combination immunotherapy.
Authors: Martin J Rutkowski; Michael E Sughrue; Ari J Kane; Steven A Mills; Andrew T Parsa Journal: Mol Cancer Res Date: 2010-09-24 Impact factor: 5.852
Authors: Natasa Obermajer; Ravikumar Muthuswamy; Kunle Odunsi; Robert P Edwards; Pawel Kalinski Journal: Cancer Res Date: 2011-10-24 Impact factor: 12.701
Authors: Michael Dechant; Wencke Weisner; Sven Berger; Matthias Peipp; Thomas Beyer; Tanja Schneider-Merck; Jeroen J Lammerts van Bueren; Wim K Bleeker; Paul W H I Parren; Jan G J van de Winkel; Thomas Valerius Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris Journal: Nat Rev Immunol Date: 2017-09-18 Impact factor: 53.106
Authors: Stephanie K Doerner; Edimara S Reis; Elaine S Leung; Justine S Ko; Jason D Heaney; Nathan A Berger; John D Lambris; Joseph H Nadeau Journal: Mol Cancer Res Date: 2016-08-17 Impact factor: 5.852
Authors: Ines Llaudo; Miguel Fribourg; M Edward Medof; Patricia Conde; Jordi Ochando; Peter S Heeger Journal: Am J Transplant Date: 2018-09-17 Impact factor: 8.086
Authors: Andrea Facciabene; Francesco De Sanctis; Stefano Pierini; Edimara S Reis; Klara Balint; John Facciponte; Jens Rueter; Masahiro Kagabu; Paola Magotti; Evripidis Lanitis; Robert A DeAngelis; Ronald J Buckanovich; Wenchao C Song; John D Lambris; George Coukos Journal: Oncoimmunology Date: 2017-06-08 Impact factor: 8.110